Kazmira Therapeutics has officially launched a prescription-only cannabinoid (CBD) pharmacy, Kazmira Pharmacy. This licensed and LegitScript certified 503A compounding pharmacy specializes in pure compounded cannabidiol without any trace of tetrahydrocannabinol (THC), the intoxicating component in hemp.
Co-founder and Co-CEO Priyanka Sharma, Ph.D., said, "The goal is to move CBD from an over-the-counter product to evidence-based, pharmacy-dispensed medicine," Sharma noted. "Now, providers can work with their patients to prescribe personalized treatment that is best for their unique health concerns."
Sharma explained the impact of ultra pure CBD has been studied on a variety of health conditions, including pain management, anxiety disorders, and substance abuse disorders. Prescription-only CBD could make a difference for patients who may not have responded well to other treatments on the market.
© Kazmira Pharmacy
The timing for Kazmira's pharmacy is ideal given hemp and marijuana laws have been front and center in national debates. In December 2025, President Trump signed an Executive Order that will reschedule cannabis to Schedule III drug, effectively banning over-the-counter products currently on the market that contain more than 0.4 milligrams of THC.
"Kazmira is not another CBD company reacting to regulatory change. We have an intentional, infrastructure-first healthcare launch that demonstrates how CBD can be integrated into clinical care without relying on wellness loopholes, retail distribution, or unapproved drug claims," Sharma explained. "As scrutiny increases and legacy hemp models face pressure, healthcare stakeholders need clarity on what survives the transition. This launch offers a credible blueprint for what the future of CBD looks like when treated as medicine, not loosely-regulated over-the-counter products."
Gautham Oroskar, MD, a medical advisor at Kazmira Therapeutics, believes the model will improve clinical adoption of CBD as a medical treatment.
"When you take intoxication, impairment, and drug-testing concerns off the table, physicians can evaluate how their patients respond to CBD the same way they evaluate any other therapeutic compound," he said. "It becomes a therapeutic tool in their toolkit with a defined mechanism of action, not a supplement with weak clinician oversight."
For more information:
Kazmira Pharmacy
kazmirapharmacy.com
